1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69:631–7.
Article
2. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004; 43:1252–5.
Article
3. Saadeh C. The erythrocyte sedimentation rate: old and new clinical applications. South Med J. 1998; 91:220–5.
Article
4. Sox HC Jr, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med. 1986; 104:515–23.
5. Smith EM, Samadian S. Use of the erythrocyte sedimentation rate in the elderly. Br J Hosp Med. 1994; 51:394–7.
6. Talstad I, Scheie P, Dalen H, Röli J. Influence of plasma proteins on erythrocyte morphology and sedimentation. Scand J Haematol. 1983; 31:478–84.
Article
7. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum. 1991; 34:1065–8.
Article
8. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009; 68:954–60.
Article
9. Ward MM. Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol. 2004; 31:884–95.
10. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007; 66:1221–6.
Article
11. Tamhane A, Redden DT, McGwin G Jr, Brown EE, Westfall AO, Reynolds RJ IV, et al. Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. J Rheumatol. 2013; 40:1812–22.
Article
12. Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Clinical characteristics of patients with rheumatoid arthritis who have sustained high erythrocyte sedimentation rates after clinical remission. J Rheum Dis. 2014; 21:20–4.
Article
13. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol. 1994; 21:1227–37.
14. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. Rheumatology (Oxford). 2007; 46:975–9.
Article
15. Mäkinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis. 2005; 64:1410–3.
16. Balsa A, Carmona L, González-Alvaro I, Belmonte MA, Tena X, Sanmartí R. EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol. 2004; 31:40–6.
17. Lee YH, Lee JS, Kang ES. Defining remission of Korean patients with rheumatoid arthritis. J Rheum Dis. 2008; 15:204–11.
Article
18. Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK, et al. Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008; 58:2642–51.
Article